Edition:
United States

Cynosure Inc (CYNO.OQ)

CYNO.OQ on NASDAQ Stock Exchange Global Select Market

52.35USD
1:54pm EDT
Change (% chg)

$-0.38 (-0.72%)
Prev Close
$52.73
Open
$53.16
Day's High
$53.18
Day's Low
$52.10
Volume
20,452
Avg. Vol
91,190
52-wk High
$55.84
52-wk Low
$29.60

Latest Key Developments (Source: Significant Developments)

Cynosure to name Stephen Webber as Chief Financial Officer
Tuesday, 13 Sep 2016 08:30am EDT 

Cynosure Inc : Cynosure to name Stephen J. Webber as new chief financial officer . Stephen J. Webber will join company on October 10, 2016 as executive vice president . Webber will become CFO and chief accounting officer effective upon filing in november of quarterly report on form 10-Q for quarter ending Sept 30 .Cynosure Inc says Webber succeeds Timothy Baker, who in May announced his planned retirement to pursue philanthropic interests.  Full Article

Cynosure reports record sales of $110.3 mln for the Q2 2016
Tuesday, 26 Jul 2016 08:00am EDT 

Cynosure Inc : Cynosure reports net income of $6.3 million on record sales of $110.3 million for the second quarter of 2016 . Q2 non-gaap earnings per share $0.36 . Q2 gaap earnings per share $0.27 . Q2 revenue $110.3 million versus I/B/E/S view $101.3 million .Q2 earnings per share view $0.29 -- Thomson Reuters I/B/E/S.  Full Article

Cynosure announces planned retirement of Timothy Baker
Wednesday, 25 May 2016 08:30am EDT 

Cynosure Inc : Michael r. Davin , company's chairman and chief executive officer, has been appointed president effective today . Company has initiated a search for a cfo . Baker plans to remain with cynosure through succession to help achieve a smooth transition .Cynosure announces planned retirement of timothy w. Baker as president, chief financial officer and chief operating officer.  Full Article

Cynosure receives FDA clearance to market new picosure energy delivery system for tattoos and pigmented lesions
Tuesday, 24 May 2016 08:30am EDT 

Cynosure Inc : Cynosure receives fda clearance to market new picosure® energy delivery system for tattoos and pigmented lesions .Shipments of new 1064 nm wavelength to begin in second half of 2016.  Full Article

Cynosure Inc says authorization of share repurchase
Tuesday, 9 Feb 2016 08:01am EST 

Cynosure Inc:Says board of directors has authorized the repurchase of up to $35 million.  Full Article

Cynosure Inc receives expanded FDA 510(k) clearance to market Sculpsure for non-invasive lipolysis of abdomen
Tuesday, 7 Jul 2015 08:30am EDT 

Cynosure Inc:Receives expanded FDA 510(k) clearance to market Sculpsure for non-invasive lipolysis of the abdomen.Says the technology is expected to be launched in the U.S. in the second half of 2015.  Full Article

Cynosure Inc Receives FDA 510(k) Clearance for SculpSure
Tuesday, 19 May 2015 08:30am EDT 

Cynosure, Inc:Received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market SculpSure(tm), the hyperthermic laser treatment for non-invasive lipolysis of the flanks.  Full Article

Cynosure Inc announces FDA clearance of new 532 nm laser delivery system for PicoSure
Tuesday, 24 Feb 2015 08:30am EST 

Cynosure Inc:Announced FDA 510(k) clearance of its new 532 nm Laser Delivery System for PicoSure, dual-wavelength laser system for removing tattoos of all colors in fewer treatments.  Full Article

Cynosure Inc signs exclusive agreement to market MonaLisa Touch in North America for Gynecology Indications
Tuesday, 18 Nov 2014 08:00am EST 

Cynosure Inc:Announced that it has signed an exclusive agreement with El.En. S.p.A. to market and distribute in North America the MonaLisa Touch, a carbon dioxide (CO2) laser for the treatment of vaginal atrophy.Says it expects to begin selling the product in the U.S. in the Q1 2015 through a specialty surgical sales force.  Full Article

BRIEF-Cynosure reports record sales of $110.3 mln for the Q2 2016

* Cynosure reports net income of $6.3 million on record sales of $110.3 million for the second quarter of 2016